

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

TELEPHONE: 512/536-3000  
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/536-3184




June 11, 2002

9/11/16/45  
Pool Sep  
K

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

FILE: UTSD:729US

10110099

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 11, 2002 Date	 Steven L. Highlander

Commissioner for Patents  
Washington, D.C. 20231

RE: *U.S. Patent Application No. 10/045,594 Entitled: "METHODS AND COMPOSITIONS RELATING TO MUSCLE SPECIFIC SARCOMERIC CALCINEURIN-BINDING PROTEINS (CALSARCINS)" - by Eric Olson and Norbert Frey*

RECEIVED

Commissioner:

JUN 24 2002

Enclosed for filing in the above-referenced patent application is:

TECH CENTER 1600/2900

- (1) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.


Commissioner for Patents

June 11, 2002

Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10110099/SLH.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Steven L. Highlander", is written over a circular stamp. The signature is fluid and somewhat stylized, with a long horizontal stroke extending to the right.

Steven L. Highlander  
Reg. No. 37,642

SLH/cpj

Encl.: As stated



CERTIFICATE OF MAILING  
37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

June 11, 2002  
Date of Deposit

Steven L. Highlander

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*In re* Application of:

Eric Olson and Norbert Frey

Serial No.: 10/045,594

Filed: November 7, 2001

For: METHODS AND COMPOSITIONS  
RELATING TO MUSCLE SPECIFIC  
SARCOMERIC CALCINEURIN-  
BINDING PROTEINS (CALSARCINS)

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:729US/SLH

**RECEIVED**

JUN 24 2002

**TECH CENTER 1600/2900**

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES DATED APRIL 11, 2002**

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated April 11, 2002 for which the due date is June 11, 2002.


It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10110099/SLH.

**RESPONSE TO NOTICE**

Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Applicants believe that the attached documents fully responds to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: June 11, 2002




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/045,594	11/07/2001	Eric Olson	UTSD:729US

CONFIRMATION NO. 8497

## FORMALITIES LETTER



\*OC000000007845607\*

Steven L. Highlander  
Fulbright & Jaworski L.L.P.  
Suite 2400  
600 Congress Avenue  
Austin, TX 78701

Date Mailed: 04/11/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900


*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

# 8



CERTIFICATE OF MAILING 37 C.F.R. §1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231, on the date below:	
<u>June 11, 2002</u> Date of Deposit	 Steven L. Highlander

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*In re* Application of:  
Eric Olson and Norbert Frey

Serial No.: 10/045,594

Filed: November 7, 2001

For: METHODS AND COMPOSITIONS  
RELATING TO MUSCLE SPECIFIC  
SARCOMERIC CALCINEURIN-  
BINDING PROTEINS (CALSARCINS)

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:729US/SLH

**STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)**

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Commissioner:


RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3184

Date: June 11, 2002